Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
BioBlast®
Biopharma News
Biosimilar Deals 2025
Biosimilar Deals 2026
Biosimilars Deals 2023
Biosimilars Deals 2024
Chantal Savage
Diversity
Helen Macpherson
Intranet
Masterclasses
Other Podcasts
Other Updates
Our Awards
Patent Case Summaries
Patent Litigation
Patents
Paul Johns
PipCast®
PTE
Sally Paterson
Trade Marks
Webinars

Home / News / BioBlast®

Pearce IP BioBlast

 

Explore our interactive biosimilar news updates, collating tailored reports by brand, INN, originator/biosimilar applicant, litigation, region, or date. Alternatively, review our weekly BioBlast® updates below.

2026

November 16, 2026

On 16 November 2026, Sandoz announced the US launch of Enzeevu® (aflibercept-abzv) 2 mg, biosimilar to Regeneron/Bayer’s Eylea®, 2 mg.  Enzeevu® is available in a pre-filled syringe and is approved for the treatment of various retinal diseases including nAMD, macular oedema following retinal vein occlusion, diabetic retinopathy and diabetic macular oedema.

Sandoz has entered into a multi-year private-label agreement for Enzeevu®, under which Sandoz will manufacture Enzeevu® for commercialisation under a private label beginning in mid-2027.

Enzeevu® was approved by the FDA in August 2024.  In the same month, Regeneron commenced BPCIA litigation against Sandoz in the US District Court for the District of New Jersey asserting infringement of 46 US patents relating to aflibercept.  A settlement of the BPCIA litigation was announced on 9 September 2025, with Sandoz permitted to launch its aflibercept biosimilar in Q4 2026.

Enzeevu® is the third aflibercept biosimilar on the US market, following the launch of Amgen’s Pavblu® in October 2024 (following the US Court of Appeals’ denial of Regeneron’s injunction application) and Biocon’s Yesafili™ in August 2026 (under an April 2025 settlement).

A stream of further upcoming aflibercept biosimilar launches is expected in the US resulting from litigation settlements, including Formycon/Klinge’s Ahzantive® (approved June 2024, due to launch Q4/2026), Celltrion’s Eydenzelt® (approved October 2025, due to launch Q4/2026), Alvotech/Teva’s AVT06 (due to launch Q4/2026, subject to regulatory approval), and Samsung Bioepis’ Opuviz® (approved May 2024, due to launch from January 2027).

November 13, 2026

On 13 November 2026, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) announced the outcomes of its November 2026 meeting, including positive opinions for the following two biosimilars to Novo Nordisk’s NovoRapid® (insulin aspart):

  • Garzulys®, for which the EU marketing authorisation applicant is SciencePharma Sp. z.o.o; and
  • Donrafylix™, with the EU marketing authorisation applicant being Belgian pharmaceutical company, Kuraci.

Both biosimilars are indicated for treatment of diabetes mellitus in adults, adolescents and children aged 1 year and above.

The positive CHMP opinion for Garzulys® follows FDA approval for the biosimilar in July 2026.  Garzulys™ was developed by China-based Tonghua Dongbaou Pharmaceutical.  The US Biologics License Application (BLA) is held by Emerge Biosciences and Meitheal Pharmaceuticals is the US regulatory agent with exclusive US commercialisation rights for Garzulys® under a 2023 licence agreement with Emerge.

Insulin aspart biosimilars approved in Europe include Sandoz’s Dazparda® (approved May 2026), Biocon’s Kirsty® (previously Kixelle®) (approved February 2021), and Insulin aspart Sanofi (approved June 2020).

November 12, 2026

On 12 November 2026, Celltrion announced that it has filed an application with Australia’s Therapeutic Goods Administration for approval of Besequma® (CT-P55), biosimilar to Novartis’ Cosentyx® (secukinumab).  The application is for all approved indications of Cosentyx®.

Celltrion’s Australian application follows its submission of marketing approval applications for CT-P55 in Europe and the US (July 2026), Korea (June 2026) and Canada (May 2026).

Celltrion presented results from its Phase 1 trial for CT-P55 in September 2025.  In February 2026, Celltrion received approval from the EMA to reduce patient numbers enrolled in its global Phase 3 clinical trial for CT-P55.

On 26 October 2026, Bio-Thera announced that it received the first approval for a secukinumab biosimilar by any major regulatory agency in the world when it obtained marketing authorisation in China for BAT2306, marketed as Youzhuomei™.  BAT2306/Youzhuomei™ is approved in China for psoriasis, ankylosing spondylitis and psoriatic arthritis.

Secukinumab biosimilars are under development by at least Taizhou Mabtech Pharmaceutical (phase 1 trial of CMAB015 completed in 2023) and Livzon Pharmaceutical Group (phase 3 clinical trial of LZM012 in plaque psoriasis).  In June 2026, CSPC Pharmaceutical announced that China’s National Medical Products Administration (NMPA) had accepted a marketing authorisation application for its Secukinumab Injection.

November 12, 2026

On 12 November 2026, Lupin and Sandoz announced the launch of Ranluspec®, biosimilar to Genentech’s Lucentis® (ranibizumab), in Europe, excluding Germany.  Ranluspec® is developed, manufactured and registered by Lupin and is commercialised by Sandoz in the EU (excluding Germany) under an August 2025 agreement.

Ranluspec® was approved by the European Commission in February 2026 in vial and pre-filled syringe presentations and is indicated for the treatment of nAMD, visual impairment due to DME, proliferative diabetic retinopathy, visual impairment due to macular oedema secondary to retinal vein occlusion (RVO) and visual impairment due to choroidal neovascularisation.

Ranibizumab biosimilars already approved and launched in Europe include Samsung Bioepis’ Byooviz® (approved August 2021, commercially available since March 2023), STADA/Xbrane’s Ximluci® (launched in April 2023, following November 2022 approval), and Formycon’s Ranivisio® (approved August 2022, commercialised in by Teva).  Lupin’s Vislyfa® (ranibizumab) was recommended by the CHMP in May 2026 and approved in July 2026, while Accord’s Fovlussea® and Intas’ Rexatilux® received positive CHMP opinions in October 2026 and April 2026 (approved June 2026), respectively.

November 9, 2026

On 9 November 2026, Celltrion announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for an expanded indication for Steqeyma®, biosimilar to Janssen’s Stelara® (ustekinumab), to treat Crohn’s disease and ulcerative colitis in children aged two and older.

Steqeyma® is already approved in Europe for Crohn’s disease in paediatric patients weighing at least 40 kilograms, as well as for adult Crohn’s disease and ulcerative colitis.  It is also approved for plaque psoriasis in adults and children and psoriatic arthritis in adults.

Celltrion has launched Steqeyma® in Europe (November 2024), the US (March 2025), Japan (July 2025) and Australia (listed on the PBS from 1 August 2025).

November 9, 2026

On 9 November 2026, Shanghai Henlius announced that Brazil’s National Health Surveillance Agency (Anvisa) has approved Poherdy®, biosimilar to Genentech’s Perjeta® (pertuzumab).  Poherdy® is the first biosimilar pertuzumab approved in Brazil.

Poherdy® (HLX11) was developed by Shanghai Henlius, which licensed the exclusive commercialisation rights to Organon under a 2022 agreement for all regions outside China, Macau, Hong Kong and Taiwan.

Poherdy® was the first pertuzumab biosimilar approved in the US (November 2025) and EU (April 2026).  In the US, a BPCIA patent challenge by Genentech/Roche against Henlius/Organon regarding Poherdy® was settled in January 2026 on confidential terms, with no details of any planned US launch of Poherdy® being disclosed to date.  In China, HLX11 was approved in May 2026 as Hanbeiyou®.

In September 2026, Biocon announced that, in partnership with Brazilian state-owned pharmaceutical laboratory, Bahiafarma, and Brazilian biotechnology company, Bionovis, it has entered a 10-year contract to supply Bmab 1500 (pertuzumab) in Brazil.  Biocon signed a global settlement and licence agreement with Genentech for Bmab 1500 (Pebrilzo®) in October 2026, permitting Biocon to launch Pebrilzo® in the EU/UK in Q1/2027, in the US in Q3/2028 and in 2026-2028 in other Rest of World countries (or earlier in certain circumstances).

Approvals for pertuzumab biosimilars have been granted in India for Intas’ product (December 2024), Zydus’ Sigrima™ (June 2024, subject to ongoing litigation) and Enzene’s Pertuza®/Perzea® (launched September 2025).  In Russia, Biocad’s Pertuvia™ (May 2025, subject to litigation) and R-Pharm’s Persinthia™ (February 2026) are approved.

In June 2026, EirGenix announced that it signed an agreement with an undisclosed company for the licensing and commercialisation of its pertuzumab biosimilar, EG1206A, in Japan.  This followed a 2025 global commercialisation deal with Sandoz for EG1206A, excluding Japan and a number of other countries in Asia.

November 9, 2026

On 9 November 2026, Sandoz announced that it has launched Owozy™, a generic version of Novo Nordisk’s Ozempic® (semaglutide), in Brazil.  This is the first semaglutide launch for Sandoz worldwide.

Owozy™ was developed by Malta-headquartered Adalvo and was approved in Brazil on 29 July 2026 for the treatment of type 2 diabetes.  According to Sandoz, Owozy™ is among the earliest new semaglutide treatment options available in Brazil, which has a GLP-1 market estimated to be worth USD 2.7 billion, with more than 16.5 million Brazilians living with diabetes.

The launch of Owozy™ in Brazil follows the approval of Sandoz’s generic semaglutide in Canada in September 2026, which is expected to launch by the end of 2026.

A number of generic semaglutide products have now been launched around the world.  In March 2026, Dr Reddy’s, Zydus, Alkem, Sun Pharma and Glenmark launched generic semaglutide products on the Indian market, following the expiry of Novo Nordisk’s core Indian patent for semaglutide.  Generic semaglutide products were also launched in Canada in May 2026 by Apotex and Dr Reddy’s.  Sun Pharma’s generic semaglutide injection was approved in South Africa (announced 15 July 2026), with launch following shortly thereafter.

Apotex received the first US FDA Tentative Approval for its generic semaglutide ANDA in April 2026, giving it an opportunity to be one of the first to launch generic Ozempic® in the US following expiry of Novo Nordisk’s exclusivity/patents.  Novo Nordisk has sued Apotex in the US in relation to generic Rybelsus®, Ozempic® and Wegovy®, alleging patent infringement, with the three cases being consolidated in June 2026.  Novo Nordisk also commenced Hatch Waxman litigation against Cipla in July 2026 in relation to generic semaglutide products.

November 8, 2026

On 8 November 2026, GlycoNex announced that a marketing authorisation application for SPD8, biosimilar to Amgen’s Prolia® (denosumab) was submitted to Japan’s Pharmaceuticals and Medical Devices Agency (PDMA).

SPD8 was co-developed by GlycoNex with Mitsubishi Gas Chemical.  GlycoNex retains sales, distribution and commercialisation rights to SPD8 in all markets outside Japan and is actively seeking commercialisation partners in these markets.

The submission of the application follows GlycoNex’s June 2026 announcement that SPD8 met the primary endpoint in a Phase 3 osteoporosis study conducted in Japan, demonstrating therapeutic equivalence to Prolia®.

According to GlycoNex, SPD8 could receive regulatory approval in Japan at the end of 2027.  GlycoNex is also preparing for a regulatory submission for SPD8 in Taiwan.

There is one approved denosumab biosimilar in Japan to date, Alvotech/Fuji Pharma’s AVT03 (DENOSUMAB BS 120 mg/1.4 mL in a vial for subcutaneous injection; September 2025), biosimilar to Daiichi Sankyo’s Ranmark® (marketed in other countries as Amgen’s Xgeva®).  On 30 October 2026, China-headquartered Boan Biotech announced that it has licensed BA6101 (denosumab), biosimilar to Amgen’s Prolia®, to an undisclosed partner for Japan.

November 6, 2026

On 6 November 2026, Bio-Thera Solutions announced that China’s National Medical Products Administration (NMPA) has approved BAT2506, biosimilar to Janssen’s Simponi® (golimumab), which will be marketed under the name 阿舒立® (Ashuli).  This is the first golimumab biosimilar to be approved in China.

BAT2506 was also the first (and to date remains the only) biosimilar golimumab approved in the US (in May 2026), where it will be commercialised by Accord BioPharma under the names Immgolis™ (referencing Simponi®) and Immgolis Intri™ (referencing Simponi® Aria).  On 30 September 2026, the US District Court for the District of Delaware granted Janssen a preliminary injunction preventing Accord/Bio-Thera from launching Immgolis™ and Immgolis Intri™ in the US during the term of the relevant patent(s).  The preliminary injunction was granted in the context of BPCIA proceedings commenced by Janssen against Accord and Bio-Thera on 3 March 2026, alleging that Immgolis™ and Immgolis Intri™ infringe 17 Janssen patents.  Accord and Bio-Thera have appealed the injunction decision (which is not yet publicly available), with a Notice of Appeal filed on 1 October 2026.

BAT2506 was approved in Europe, under the name Gotenfia®, in February 2026.  Gotenfia® is being commercialised in Europe by STADA under a May 2024 agreement.  It was the second golimumab biosimilar to be approved in Europe, following the approval of Alvotech/Advanz’s Gobivaz® (AVT05) in November 2025.

Bio-Thera has entered commercialisation agreements for BAT2506, including with Intas for Latin America (announced March 2026) and Canada ( announced October 2025), SteinCares for Latin America (announced March 2024) and Dr Reddy’s for South East Asia (announced March 2025).

November 5, 2026

On 5 November 2026, Celltrion announced that it launched three biosimilars in Brazil in October 2026: Qoyvolma®, biosimilar to Janssen’s Stelara® (ustekinumab), and Stoboclo® and Osenvelt®, biosimilars to Amgen’s Prolia® and Xgeva® (denosumab), respectively.

Qoyvolma® is approved for the treatment of plaque psoriasis, psoriatic arthritis, Crohn’s disease and ulcerative colitis.  Stoboclo® and Osenvelt® are approved for the same indications as the reference medicine.

With this launch, Celltrion’s product range in Brazil has expanded to a total of 10 products, including infliximab, adalimumab, and omalizumab biosimilars.  Celltrion is planning to launch Eydenzelt®, biosimilar to Regeneron/Bayer’s Eylea® (aflibercept) and Avtozma®, biosimilar to Roche’s Actemra® (tocilizumab), in Brazil before the end of the year.

The launch of Celltrion’s ustekinumab biosimilar follows news that Biocon’s Yesintek® (ustekinumab) was permitted to enter the Brazilian market “with immediate effect” following a settlement agreement entered into by Biocon and Janssen in October 2026.  Bio-Thera and Biomm entered a licensing agreement for Bio-Thera’s BAT2206 (ustekinumab) in Brazil in June 2023.

There have been at least two reported denosumab biosimilar approvals in Brazil to date.  Sandoz’s Denbonli® (referencing Amgen’s Prolia®) and Wyost® (referencing Amgen’s Xgeva®) received approval in September 2025.  Abbott/mAbxience received approval for two unnamed denosumab biosimilars in June 2026.  There are denosumab biosimilars under development for the Brazilian market by at least Mabwell/Cristália (strategic agreement entered August 2024) and Boan Biotech and an unnamed strategic partner (strategic agreement entered November 2024).

BioBlast® extract From November 5, 2026 to November 16, 2026

BioBlast® Editor and Contributing Author

Naomi Pearce and Chantal Savage

Naomi Pearce and Chantal Savage

Get our Pearce IP Blogs & BioBlast® sent directly to your inbox

Subscribe to our Pearce IP Blogs and BioBlast® to receive our updates via email.